Abacavir is a nucleoside analogue reverse transcriptase inhibitor used in 
combination with other antiretroviral drugs for the treatment of HIV 
1-infection. Approximately 3% of patients who receive abacavir develop an 
idiosyncratic hypersensitivity reaction. The most common symptoms are fever, 
skin rash and gastrointestinal disorders. Respiratory symptoms occurred in 
approximately 20% of patients who have hypersensitivity reaction. We describe 
the first case, to our knowledge, of hypesensitivity reaction characterized by 
enanthema and fever without skin rash promptly resolved after discontinuation of 
abacavir